Patrick B. Lappin

2.3k citations

26 papers · 674 indexed · h-index 16

Rheumatology top 10%
Immunology
Oncology
- Cancer Cells and Metastasis 3
- Cancer-related Molecular Pathways 2
Cancer Research
- Cancer Genomics and Diagnostics 2
Radiology, Nuclear Medicine and Imaging top 10%
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 4
Biochemistry
- Eicosanoids and Hypertension Pharmacology 2
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 2
- Advanced Breast Cancer Therapies 2
Hepatology
- Hepatocellular Carcinoma Treatment and Prognosis 2

Co-authors: Thomas A. Zanardi James G. Christensen Brett H. Simmons Farbod Shojaei Joseph H. Lee Marta L. Corcoran Wendy Halpern John Zhong
Cited by: Rheumatology Immunology Oncology
Journals: Toxicology and Applied Pharmacology (3 papers)Clinical Cancer Research (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)
Partner nations: United States France

In The Last Decade

Patrick B. Lappin

26 papers receiving 656 citations

Peers

Countries citing papers authored by Patrick B. Lappin

Since Specialization

Citations

This map shows the geographic impact of Patrick B. Lappin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick B. Lappin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick B. Lappin more than expected).

Fields of papers citing papers by Patrick B. Lappin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick B. Lappin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick B. Lappin. The network helps show where Patrick B. Lappin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Patrick B. Lappin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick B. Lappin Line = papers co-authored together Patrick B. Lappin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143) Scientific Reports ·Yanyan Zhang,Luis Antonio García García,Ruoping Tang,Yin Gu,Patrick B. Lappin,L R DeBuys,Shu‐Hui Liu,Tod Smeal,Valeria R. Fantin,Stéphane de Botton,Ollivier Legrand,François Delhommeau,Flavia Pernasetti,Fawzia Louache	2017	31
2	Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility PLoS ONE ·Ricardo Martínez,Alessandra Blasina,Jill Hallin,Wenyue Hu,Abeer Zein,Shamebo Tsegaye,Robert L. Hoffman,Sean T. Murphy,Matthew A. Marx,Gina M. Yanochko,L R DeBuys,Dac M. Dinh,Sergei Timofeevski,Zhou Zhu,政美田中,Patrick B. Lappin,Brion W. Murray	2015	29
3	Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer Cancer Chemotherapy and Pharmacology ·Pasquale Cirone,Catharine J. Andresen,Jeetendra Eswaraka,Patrick B. Lappin,Cedo M. Bagi	2014	26
4	Crizotinib Reduces the Rate of Dark Adaptation in the Rat Retina Independent of ALK Inhibition Toxicological Sciences ·Chang‐Ning Liu,Nagappan Mathialagan,Patrick B. Lappin,Frédéric Martin-Achard,Devrim Ertürk,Lechuang Chen,Theodore R. Johnson,Wenyue Hu,Wang Qing Yin	2014	20
5	Expression of Proto-Oncogene cFMS Protein in Lung, Breast, and Ovarian Cancers Applied immunohistochemistry & molecular morphology ·Satoko Kakiuchi-Kiyota,Patrick B. Lappin,C Rabbia,Paul W. Brown,ประชุม เกตุแก้ว,Anne Ryan,Nagappan Mathialagan	2013	8
6	Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation PLoS ONE ·Douglas D. Fang,Cathy C. Zhang,Yin Gu,Jitesh P. Jani,Joan Cao,Konstantinos Tsaparikos,Jing Yuan,Houde Xu,Amy Jackson-Fisher,Débora D. da Silva,Patrick B. Lappin,Tomoko Hayashi,Richard B. Schwab,Anthony Wong,Muhammad Aasim Ullah,Shubha Bagrodia,L. Jovovic,Steve Bender,James G. Christensen,Todd VanArsdale	2013	33
7	Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models Clinical Cancer Research ·Cathy C. Zhang,Adam Pavlı́c̀ek,Qin Zhang,Maruja E. Lira,Cory L. Painter,Zhengming Yan,Xianxian Zheng,Nathan V. Lee,Mark Ozeck,Ming Qiu,Débora D. da Silva,Patrick B. Lappin,Anthony Wong,Paul A. Rejto,Tod Smeal,James G. Christensen	2012	53
8	HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis Cancer Letters ·Farbod Shojaei,Brett H. Simmons,Joseph H. Lee,Patrick B. Lappin,James G. Christensen	2012	50
9	Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer Journal of Experimental & Clinical Cancer Research ·Farbod Shojaei,Nathan Scott,Xiaolin Kang,Patrick B. Lappin,N Barat,Anna M. M. Blando,Brett H. Simmons,Е. А. Редина,Joseph H. Lee,Simon Bergqvist,Eugenia Kraynov	2012	53
10	Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey Toxicology ·Scott P. Henry,Mark D. Johnson,Thomas A. Zanardi,Robert Fey,Diana J. Auyeung,Patrick B. Lappin,Arthur A. Levin	2012	44
11	Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice Cancer Chemotherapy and Pharmacology ·Brett H. Simmons,Joseph H. Lee,Cassandra Lydén,Anand Giddabasappa,Evaldo A. Kuiava,Anthony Wong,Patrick B. Lappin,Jeetendra Eswaraka,Julie L.C. Kan,James G. Christensen,Farbod Shojaei	2012	19
12	[18F]FLT–PET Imaging Does Not Always “Light Up” Proliferating Tumor Cells Clinical Cancer Research ·Cathy C. Zhang,Zhengming Yan,Wenlin Li,Kyle Kuszpit,Cory L. Painter,Qin Zhang,Patrick B. Lappin,Tim Nichols,Maruja E. Lira,Timothy Affolter,Puspa Eka Ayu Febriana,Carleen Cullinane,Mary E. Spilker,Kenneth Zasadny,Peter J. O’Brien,Dan A. Chrisman,Anthony Wong,James G. Christensen	2011	62
13	Urethral Bulking With Polymethylmethacrylate Microspheres for Stress Urinary Incontinence: Tissue Persistence and Safety Studies in Miniswine Urology ·Gottfried Lemperle,Patrick B. Lappin,Zhu Shiyue,Stefan M. Lemperle	2011	16
14	Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects Toxicological Sciences ·Wendy Halpern,Patrick B. Lappin,Thomas A. Zanardi,Wendy Cai,Marta L. Corcoran,John Zhong,Kevin P. Baker	2006	113
15	Ovarian Choriocarcinoma in a Rhesus Monkey Associated with Elevated Serum Chorionic Gonadotropin Levels Veterinary Pathology ·Cindy Farman,Kurt Benirschke,Sanyukta Gawande,Patrick B. Lappin	2005	17
16	The Response of Pulmonary Vascular Endothelial Cells to Monocrotaline Pyrrole: Cell Proliferation and DNA Synthesisin Vitroandin Vivo Toxicology and Applied Pharmacology ·Patrick B. Lappin,Kerry L. Ross,Louis E. King,Pamela J. Fraker,Robert A. Roth	1998	15
17	Vitamin A or Zymosan Pretreatment Attenuates α-Naphthylisothiocyanate-Induced Liver Injury Toxicology and Applied Pharmacology ·Marc B. Bailie,Paul A. Jean,Patrick B. Lappin,J. Chen,Thomas M. Schmidt,Frederic Moulin,R A Roth	1995	6
18	Platelets and α-Naphthylisothiocyanate-Induced Liver Injury Toxicology and Applied Pharmacology ·Marc B. Bailie,Julia M. Pearson,Patrick B. Lappin,Jiao Hong-shen,Robert A. Roth	1994	12
19	Disseminated trichosporonosis in a neutropenic murine model Mycopathologia ·Duane R. Hospenthal,Tesfaye Belay,Patrick B. Lappin,Alvin L. Rogers,M. Kennedy	1993	9
20	Difficult Dermatologic Diagnosis Journal of the American Veterinary Medical Association ·Patrick B. Lappin,Robert W. Dunstan	1992	2

About Patrick B. Lappin

Patrick B. Lappin is a scholar working on Biochemistry, Small Animals, Hepatology, Oncology and Dermatology, having authored 26 papers that have together received 674 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (4 papers), Cancer Cells and Metastasis (3 papers), Eicosanoids and Hypertension Pharmacology (2 papers), Cancer Genomics and Diagnostics (2 papers), Cancer-related Molecular Pathways (2 papers), Lung Cancer Treatments and Mutations (2 papers), Advanced Breast Cancer Therapies (2 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Rheumatology (101 citations), Immunology (137 citations), Oncology (174 citations), Cancer Research (92 citations) and Radiology, Nuclear Medicine and Imaging (127 citations). Patrick B. Lappin has collaborated with scholars based in United States and France. Frequent co-authors include Thomas A. Zanardi, James G. Christensen, Brett H. Simmons, Farbod Shojaei, Joseph H. Lee, Marta L. Corcoran, Wendy Halpern, John Zhong, Wendy Cai and Kevin P. Baker. Their work appears in journals such as Toxicology and Applied Pharmacology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Toxicological Sciences and Toxicologic Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact